S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
OTCMKTS:ATMS

Artemis Therapeutics (ATMS) Stock Forecast, Price & News

$0.22
0.00 (0.00%)
(As of 06/5/2023 ET)
Compare
Today's Range
$0.22
▼
$0.22
50-Day Range
$0.17
▼
$1.89
52-Week Range
$0.11
▼
$5.00
Volume
N/A
Average Volume
2,942 shs
Market Capitalization
$24.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest

ATMS stock logo

About Artemis Therapeutics (OTCMKTS:ATMS) Stock

Artemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.

Receive ATMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATMS Stock News Headlines

May 8, 2023 | msn.com
Marker Therapeutics gets new chief medical officer
April 27, 2023 | finance.yahoo.com
ARTEMIS, a soccer-playing humanoid robot, is ready for the pitch
June 5, 2023 | Legacy Research (Affiliate) (Ad)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
April 23, 2023 | usatoday.com
SpaceX Starship, larger and more powerful than Artemis SLS, explodes on first launch attempt
March 18, 2023 | theguardian.com
Nasa reveals new spacesuit for Artemis moon landing
January 7, 2023 | finance.yahoo.com
Artemis Therapeutics Inc. (ATMS)
November 16, 2022 | cbsnews.com
NASA managers order review of hurricane-damaged insulation before moon rocket launch
November 10, 2022 | msn.com
NASA’s Artemis I suffers ‘very minor’ damage from Nicole
June 5, 2023 | Legacy Research (Affiliate) (Ad)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
October 10, 2022 | reuters.com
Artemis Therapeutics Inc
September 27, 2022 | yahoo.com
Artemis I leaves launch pad ahead of Hurricane Ian
August 18, 2022 | news.yahoo.com
Nasa’s Artemis 1 moon mission explained
August 6, 2022 | yahoo.com
NASA's Artemis I moon mission includes educational, cultural, and commemorative mementos
June 2, 2022 | finance.yahoo.com
NASA Selects New Instruments for Priority Artemis Science on Moon
May 6, 2022 | msn.com
Washington plays key role In NASA's Artemis missions
March 25, 2022 | yahoo.com
Cannes Chooses Former WarnerMedia Exec Iris Knobloch To Succeed Pierre Lescure As President
July 8, 2021 | in.finance.yahoo.com
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma
April 30, 2021 | in.finance.yahoo.com
LendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive Year
April 30, 2021 | ca.finance.yahoo.com
Caution: Most Stocks Fail! Do This to Build a Winning Stock Portfolio
April 29, 2021 | au.finance.yahoo.com
Essex Communities Announces New Leadership Structure to Accommodate Rapid Growth
April 29, 2021 | au.finance.yahoo.com
‘The Falcon and Winter Soldier’ fails to pay off on its initial promise
March 25, 2021 | yahoo.com
Another piebald deer stops by a trail camera for a photo
March 25, 2021 | yahoo.com
Mum selling her possessions to fund £35K surgery before rare condition leaves her paralysed
November 18, 2020 | seekingalpha.com
Lineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside
January 21, 2019 | finance.yahoo.com
Artemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections
January 21, 2019 | finance.yahoo.com
New Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
January 21, 2019 | finance.yahoo.com
Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
See More Headlines

ATMS Price History

ATMS Company Calendar

Today
6/05/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Miscellaneous chemical products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ATMS
CUSIP
N/A
CIK
1062128
Web
www.artemis-therapeutics.com
Phone
(646) 233-1454
Fax
800-253-5177
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,360,000.00
Net Margins
-299.54%
Pretax Margin
-299.54%
Return on Equity
N/A
Return on Assets
-425.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.15
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$310,000.00
Price / Sales
79.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-21.99

Miscellaneous

Outstanding Shares
112,034,000
Free Float
103,687,000
Market Cap
$24.64 million
Optionable
Not Optionable
Beta
-1.92

Key Executives

  • Shimon Citron
    Chief Executive Officer & Director
  • Haim Tabak
    Chief Operating Officer
  • David Dana
    Chief Financial Officer
  • Dana Wolf
    Chief Medical Officer

Key Competitors

View All Competitors













ATMS Stock - Frequently Asked Questions

How have ATMS shares performed in 2023?

Artemis Therapeutics' stock was trading at $1.16 at the beginning of 2023. Since then, ATMS shares have decreased by 81.0% and is now trading at $0.2199.
View the best growth stocks for 2023 here.

When is Artemis Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ATMS earnings forecast.

What is Artemis Therapeutics' stock symbol?

Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

How do I buy shares of Artemis Therapeutics?

Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artemis Therapeutics' stock price today?

One share of ATMS stock can currently be purchased for approximately $0.22.

How much money does Artemis Therapeutics make?

Artemis Therapeutics (OTCMKTS:ATMS) has a market capitalization of $24.64 million and generates $310,000.00 in revenue each year.

How can I contact Artemis Therapeutics?

Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The official website for the company is www.artemis-therapeutics.com. The company can be reached via phone at (646) 233-1454, via email at ir@artemis-therapeutics.com, or via fax at 800-253-5177.

This page (OTCMKTS:ATMS) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -